Send us Feedback

Dendreon (DNDN)
Analysis
Data
Financials
QUOTE AND NEWS
Dendreon files BLA for Provenge
FierceBiotech  Nov 2  Comment 
Seattle-based Dendreon (DNDN) has filed for FDA approval of the prostate cancer drug Provenge, taking another big step as it builds the framework for a national distribution system for the new therapy. "With the BLA submission complete, we have...
Dendreon Resubmits Provenge to FDA: BioBuzz
TheStreet.com  Nov 2  Comment 
Dendreon Completes Submission of Biologics License Application for PROVENGE
GenEng News  Nov 2  Comment 
Dendreon to Hold Conference Call on Wednesday, November 11, 2009 at 4:30 PM ET
PR Newswire  Oct 30  Comment 
SEATTLE, Oct. 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Wednesday, November 11, 2009 at 4:30 p.m. ET; 1:30 p.m. PT to review third quarter 2009 financial results. Access to the
Dendreon (DNDN) NewsBite - DNDN Rides The GDP Wave
Market Intelligence Center  Oct 29  Comment 
Dendreon (NGM: DNDN) opened at $25.42. So far today, the stock has hit a low of $25.26 and a high of $26.36. DNDN is now trading at $26.34, up $1.24 (4.94%). Over the last 52 weeks the stock has ranged from a low of $2.55 to a high of $30.42. DNDN...
Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
PR Newswire  Oct 29  Comment 
SEATTLE, Oct. 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following upcoming investor conferences. Merriman Investor Summit 2009 New York City Tuesday, November 10, 2009 11:00
Dendreon initiated with "buy"
newratings.com  Oct 27  Comment 
NEW YORK, October 23 (newratings.com) - Analysts at Canaccord Adams initiate coverage of Dendreon (ticker: DNDN) with a "buy" rating. The target price is set to $43. [more]
High-Frequency Trading Is Not Why You Got Screwed On That Trade
Clusterstock  Oct 13  Comment 
Matthew Goldstein at Reuters tries to cite trading in the biotech company Dendreon (DNDN) to highlight the dangers high-frequency trading poses to the average investors. On April 28, the stock plunged $24 to $7.50 in the span of 70 seconds, and...
[$] BofA Leads Banks; Dendreon Rises 4.6%
Wall Street Journal  Oct 13  Comment 
Stocks ended slightly higher Monday as traders remained optimistic about earnings season and lifted Bank of America and other financials.
($DNDN) Dendreon to Seek FDA Approval for Prostate Cancer Vaccine, Provenge
Stock Blog Hub  Oct 12  Comment 
Recently, Dendreon Corp. (DNDN) announced that it intends to file an amendment to its existing Biologic License Application (BLA) for its prostate cancer vaccine Provenge in Nov. 2009. We believe that the US Food and Drug Administration (FDA) will...
Top Roche Exec Joins Dendreon Board: BioBuzz
TheStreet.com  Oct 12  Comment 
Former Genentech exec will raise speculation that Roche wants Provenge.
Suggest other news sources for this topic
Suggest a News Source
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
Close 
Thanks for your suggestion!
 
RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 
DNDN AT A GLANCE
 
 
 
 
 
 
 
 

Dendreon Corporation (DNDN) is a biotechnology company with a focus on developing drugs for cancer. Its most advanced product is Provenge (Sipuleucel-T), a therapeutic vaccine candidate being developed for the treatment of prostate cancer. Provenge could have blockbuster potential if the ongoing clinical late-stage trial yields positive results. Dendreon will market Provenge in the U.S. on its own. And we expect Dendreon to announce a partner for Provenge in the rest of the world soon. Another important product under clinical development is APC-8024 (Lapuleucel-T, Neuvenge) for the treatment of breast, ovarian, and colorectal cancers. The company has no products on the market and derives its revenue entirely from collaborations with other companies. Based in Seattle, WA, the company employs nearly 150 people.



References

Retrieved from "http://www.wikinvest.com/stock/Dendreon_(DNDN)"
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki